Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
AgonOx, Inc.
Mayo Clinic
Virginia Commonwealth University
IGF Oncology, LLC
sigma-tau i.f.r. S.p.A.
Merck Sharp & Dohme LLC
Pharmacyclics LLC.